3-(5-苄氧基-吲哚-3-基)-丙酸 | 7394-76-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3-(5-苄氧基-吲哚-3-基)-丙酸
• 英文名称: 3-(5-benzyloxy-indol-3-yl)-propionic acid
• 英文别名: 3-(5-Benzyloxy-indol-3-yl)-propionsaeure；3-[5-(Benzyloxy)-3-indolyl]propanoic Acid；3-(5-phenylmethoxy-1H-indol-3-yl)propanoic acid
• CAS: 7394-76-5
• 化学式: C₁₈H₁₇NO₃
• 分子量: 295.338
• InChiKey: OUPMKSLXZDCYEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  62.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(5-苄氧基-吲哚-3-基)-丙酸 在 盐酸 、 palladium on activated charcoal 、 乙醇 、 一水合肼 、 溶剂黄146 、 sodium nitrite 、 苯 作用下， 反应 2.0h， 生成 5-羟基色胺
  参考文献：
  名称：

  Justoni; Pessina, Farmaco, Edizione Scientifica, 1955, vol. 10, p. 356,364

  摘要：

  DOI：
• 作为产物：
  描述：

  5-苄氧基-3-(2-羧基-乙基)-吲哚-2-羧酸 在 1,2,3,4-四氢萘 作用下， 生成 3-(5-苄氧基-吲哚-3-基)-丙酸
  参考文献：
  名称：

  Justoni; Pessina, Farmaco, Edizione Scientifica, 1955, vol. 10, p. 356,364

  摘要：

  DOI：

文献信息

• Substituted indoles and their use as integrin antagonists
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20020169200A1

  公开（公告）日：2002-11-14

  The present invention relates to novel substituted indole compounds that are antagonists of alpha V (&agr;v) integrins, for example &agr; v &bgr; 3 and &agr; v &bgr; 5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by &agr; v &bgr; 3 and &agr; v &bgr; 5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: 1 where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , D, X, W, a, m, n, i, j, k and v are defined herein.

  本发明涉及新型取代吲哚化合物，其为αV（αv）整合素的拮抗剂，例如αvβ3和αvβ5整合素，其药学上可接受的盐以及其药物组合物。这些化合物可用于治疗由αvβ3和αvβ5整合素介导的病理性状况，包括肿瘤生长、转移、再狭窄、骨质疏松、炎症、黄斑变性、糖尿病视网膜病变和类风湿性关节炎等病症。这些化合物具有以下一般式： 1 其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、D、X、W、a、m、n、i、j、k和v在此处定义。
• Sodium Iodide/Hydrogen Peroxide-Mediated Oxidation/Lactonization for the Construction of Spirocyclic Oxindole-Lactones
  作者：Guofeng Li、Liwu Huang、Jiecheng Xu、Wangsheng Sun、Junqiu Xie、Liang Hong、Rui Wang

  DOI：10.1002/adsc.201600441

  日期：2016.9.15

  The sodium iodide/hydrogen peroxide‐mediated oxidation/lactonization of indolepropionic acids was achieved, affording the corresponding spirocyclic oxindole‐lactones in moderate to high yields. This metal‐free procedure features mild reaction conditions, non‐toxicity and easy handling, with hydrogen peroxide (H2O2) as a clean oxidant.

  实现了碘化钠/过氧化氢介导的吲哚丙酸的氧化/内酯化，以中等至高收率提供了相应的螺环氧吲哚-内酯。该无金属工艺具有温和的反应条件，无毒且易于处理的特点，并且使用过氧化氢（H 2 O 2）作为清洁氧化剂。
• [EN] SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS<br/>[FR] INDOLES SUBSTITUES ET UTILISATION DE CEUX-CI COMME ANTAGONISTES D'INTEGRINE
  申请人：DIMENSIONAL PHARM INC

  公开号：WO2002060438A1

  公开（公告）日：2002-08-08

  The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: (IV) where R?1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14¿, D, X, W, a, m, n, I, j, k and v are defined herein.

  本发明涉及一种新型的取代吲哚化合物，它们是αV（αv）整合素的拮抗剂，例如αvβ3和αvβ5整合素，它们的药学上可接受的盐和制药组合物。这些化合物可用于治疗由αvβ3和αvβ5整合素介导的病理状况，包括肿瘤生长、转移、再狭窄、骨质疏松、炎症、黄斑变性、糖尿病视网膜病变和类风湿性关节炎等疾病。这些化合物具有通式：（IV），其中R?1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14¿、D、X、W、a、m、n、I、j、k和v在此定义。
• Indolealkyl derivatives of benzodioxanmethylamine
  申请人：American Home Products Corporation

  公开号：US05750724A1

  公开（公告）日：1998-05-12

  The compounds of formula I: ##STR1## wherein R.sup.1, R.sup.4 and R.sup.5 are, independently, hydrogen, alkyl, alkoxy, aralkoxy, alkanoyloxy, hydroxy, halo, trifluoromethyl, amino, mono- or di-alkylamino, alkanamido, or alkanesulfonamido; or, R.sup.1 is defined as above and R.sup.4 and R.sup.5, taken together, are ortho substituted methylenedioxy, ethylenedioxy, or propylenedioxy; R.sup.2 and R.sup.3 are, independently, hydrogen or alkyl; n is 3 or 4; or pharmaceutically acceptable salts thereof, are useful in the treatment of depression and related disorders.

  式I的化合物：##STR1## 其中R.sup.1，R.sup.4和R.sup.5独立地表示氢，烷基，烷氧基，芳基烷氧基，烷酰氧基，羟基，卤素，三氟甲基，氨基，单烷基或双烷基氨基，烷基酰胺基或烷基磺酰胺基; 或者，R.sup.1如上所定义，而R.sup.4和R.sup.5在取代位上共同为邻位取代的亚甲氧基，乙二氧基或丙二氧基; R.sup.2和R.sup.3独立地表示氢或烷基; n为3或4; 或其药学上可接受的盐，在治疗抑郁症及相关疾病方面有用。
• Substituted Indoles and Their Use as Integrin Antagonists
  申请人：Lu Tianbo

  公开号：US20070219233A1

  公开（公告）日：2007-09-20

  The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example α v β 3 and α v β 5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by α v β 3 and α v β 5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , D, X, W, a, m, n, i, j, k and v are defined herein.

  本发明涉及一种新型的取代吲哚化合物，它们是αV（αv）整合素的拮抗剂，例如αvβ3和αvβ5整合素，它们的药学上可接受的盐和制药组合物。这些化合物可用于治疗由αvβ3和αvβ5整合素介导的病理状况，包括肿瘤生长、转移、再狭窄、骨质疏松、炎症、黄斑变性、糖尿病视网膜病变和类风湿性关节炎等疾病。该化合物具有以下通式：其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、D、X、W、a、m、n、i、j、k和v在此定义。